It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...
Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...
Oxbryta has been on the market since 2019 and has been tipped to become a $1 billion-plus blockbuster at peak. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the ...
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...
Oxford Mail on MSN1h
Oxfordshire patient with sickle cell disease to receive cutting-edge treatmentAn Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback